Clinical trial
Phase II/III Study of Anti-VEGF in Neovascular AMD
NCT00021736 · Eyetech Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00021736 |
|---|---|
| Title | Phase II/III Study of Anti-VEGF in Neovascular AMD |
| Official title | Phase II/III Randomized, Double-Masked, Trial, to Establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative AMD). |
| Lead sponsor | Eyetech Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Macular Degeneration, Choroidal Neovascularization |
| Intervention type | Drug |
| Interventions | EYE001 anti-VEGF aptamer |
| Enrollment | 540 |
| Start date | Jul 1, 2001 |
| Completion | Jul 1, 2002 |
| First posted | Aug 6, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: